Skip to main content

Table 3 OPN and CD204 expression correlated with clinicopathologic characterization

From: The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression

 

OPN expression (%)

CD204 expression (%)

OPN vs. CD204 expression (%)

 

≤50%

>50%

pvalue

≤50%

>50%

pvalue

≤50% vs. ≤50%

≤50% vs. >50%

>50% vs. ≤50%

>50% vs. >50%

pvalue

Gender

  

0.550

  

0.981

    

0.795

Male

47 (59.5)

50 (54.9)

 

45 (57.0)

52 (57.1)

 

29 (61.7)

17 (56.7)

15 (50.0)

36 (57.1)

 

Female

32 (40.5)

41 (45.1)

 

34 (43.0)

39 (42.9)

 

18 (38.3)

13 (43.3)

15 (50.0)

27 (42.9)

 

Age

  

0.758

  

0.489

    

0.606

≤50 years

15 (19.0)

19 (20.9)

 

14 (17.7)

20 (22.0)

 

7 (14.9)

8 (26.7)

7 (23.3)

12 (19.0)

 

>50 years

64 (81.0)

72 (79.1)

 

65 (82.3)

71 (78.0)

 

40 (85.1)

22 (73.3)

23 (76.7)

51 (81.0)

 

Tumor Location

  

0.146

  

0.480

    

0.229

Proximal

32 (45.5)

47 (51.6)

 

39 (49.4)

40 (44.0)

 

22 (46.8)

9 (30.0)

16 (53.3)

32 (50.8)

 

Distal

47 (59.5)

44 (48.4)

 

40 (50.6)

51 (56.0)

 

25 (53.2)

21 (70.0)

14 (46.7)

31 (49.2)

 

Tumor Size (cm)

  

0.031

  

0.068

    

0.135

≤5

60 (75.9)

55 (24.1)

 

59 (74.7)

56 (61.5)

 

38 (80.9)

20 (66.7)

19 (63.3)

38 (60.3)

 

>5

19 (60.4)

36 (39.6)

 

20 (25.3)

35 (38.5)

 

25 (19.1)

21 (33.3)

14 (36.7)

31 (39.7)

 

Lauren Classification

 

0.519

  

0.738

    

0.983

Intestinal

36 (45.6)

37 (40.7)

 

35 (44.3)

38 (41.8)

 

21 (44.7)

13 (43.3)

12 (40.0)

27 (42.9)

 

Diffuse

43 (54.4)

54 (59.3)

 

44 (55.7)

53 (58.2)

 

26 (55.3)

17 (56.7)

18 (60.0)

36 (51.1)

 

Tumor Stage

  

0.379

  

0.006

    

0.004

Early

46 (58.2)

44 (48.4)

 

53 (67.1)

37 (40.7)

 

34 (72.3)

11 (36.7)

18 (60.0)

27 (42.9)

 

Advance

33 (41.8)

47 (51.6)

 

26 (32.9)

54 (59.3)

 

13 (27.7)

19 (63.3)

12 (40.0)

36 (57.1)

 

LN Metastasis

  

0.263

  

0.082

    

0.345

No

38 (48.1)

36 (39.6)

 

40 (50.6)

34 (37.4)

 

25 (53.2)

12 (40.0)

14 (46.7)

23 (36.5)

 

Yes

41 (51.9)

55 (60.4)

 

39 (49.4)

57 (62.6)

 

22 (46.8)

18 (60.0)

16 (53.3)

40 (63.5)

 

Endpoint Status

  

0.015

  

0.034

    

0.007

Survival

52 (65.8)

43 (47.3)

 

51 (64.6)

44 (48.4)

 

36 (76.6)

16 (53.3)

15 (50.0)

28 (44.4)

 

Death

27 (34.2)

48 (52.7)

 

28 (35.4)

47 (51.6)

 

11 (23.4)

14 (46.7)

15 (50.0)

35 (55.6)

 
  1. Statistically significant p values are shown in bold; p values were calculated using Fisher’s exact test.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us